These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1316 related articles for article (PubMed ID: 29044503)

  • 21. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
    Kamori T; Oki E; Shimada Y; Hu Q; Hisamatsu Y; Ando K; Shimokawa M; Wakai T; Oda Y; Mori M
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1420. PubMed ID: 34042312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
    Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
    Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma.
    Park HE; Kim JH; Cho NY; Lee HS; Kang GH
    Virchows Arch; 2017 Sep; 471(3):329-336. PubMed ID: 28597080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma.
    Harada K; Dong X; Estrella JS; Correa AM; Xu Y; Hofstetter WL; Sudo K; Onodera H; Suzuki K; Suzuki A; Johnson RL; Wang Z; Song S; Ajani JA
    Gastric Cancer; 2018 Jan; 21(1):31-40. PubMed ID: 28801853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.
    Cai L; Chen A; Tang D
    Immunology; 2024 Oct; 173(2):209-226. PubMed ID: 38517066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
    Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
    Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes.
    Burmeister K; Quagliata L; Andreozzi M; Eppenberger-Castori S; Matter MS; Perrina V; Grobholz R; Jochum W; Horber D; Moosmann P; Lehmann F; Köberle D; Ng CK; Piscuoglio S; Tornillo L; Terracciano LM
    PLoS One; 2017; 12(4):e0175563. PubMed ID: 28403223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases.
    Buckowitz A; Knaebel HP; Benner A; Bläker H; Gebert J; Kienle P; von Knebel Doeberitz M; Kloor M
    Br J Cancer; 2005 May; 92(9):1746-53. PubMed ID: 15856045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
    Noepel-Duennebacke S; Juette H; Schulmann K; Graeven U; Porschen R; Stoehlmacher J; Hegewisch-Becker S; Raulf A; Arnold D; Reinacher-Schick A; Tannapfel A
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3063-3072. PubMed ID: 33675399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computational measurement of tumor immune microenvironment in gastric adenocarcinomas.
    Chang YH; Heo YJ; Cho J; Song SY; Lee J; Kim KM
    Sci Rep; 2018 Sep; 8(1):13887. PubMed ID: 30224753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
    Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM
    Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.